Research ArticleResearch

Tramadol (with or without acetaminophen) efficacy and harm

Systematic review and meta-analysis

Jessica A. Otte, Gloria Chu, Benji Heran and Ken Bassett
Canadian Family Physician September 2025; 71 (9) 574-581; DOI: https://doi.org/10.46747/cfp.7109574

Abstract

Objective To evaluate the efficacy and safety of tramadol (with or without acetaminophen) in adult pain management compared with nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, and acetaminophen alone.

Data sources Studies were identified through a search of the entire Ovid MEDLINE database, the Ovid MEDLINE Epub Ahead of Print database, Embase, and Evidence-Based Medicine Reviews (Cochrane Central Register of Controlled Trials) from 1946 to August 19, 2022.

Study selection Included studies comprised double-blind, randomized controlled trials (RCTs) of oral tramadol (with or without acetaminophen) compared with opioids, NSAIDs, or acetaminophen for treatment of acute or chronic pain that reported at least 1 of 11 outcomes: total adverse events (AEs), fatal serious AEs (SAEs), nonfatal SAEs, patient withdrawals from the study due to AEs (WDAEs), total study withdrawals, measures of dependence or addiction, quality of life, functional improvement, 30% or more pain reduction, 50% or more pain reduction, and rescue medication use. Overall, 3184 articles were screened and 37 RCTs (21 opioid, 15 NSAID, 1 acetaminophen; N=7156; length 1 hour to 12 weeks) were included. Trials were critically appraised and assessed using the Cochrane risk of bias tool for randomized trials 1.0. Meta-analyzed outcomes were reported as risk ratios (with 95% confidence intervals [CIs]).

Synthesis Compared with opioids, tramadol with or without acetaminophen did not significantly differ in efficacy based on 50% or more or 30% or more reduction in pain or in any harm outcomes (nonfatal SAEs [risk ratio (RR)=1.35, 95% CI 0.43 to 4.20]; WDAEs [RR=0.99, 95% CI 0.80 to 1.22]; total withdrawals [RR=0.93, 95% CI 0.78 to 1.11]; or total AEs [RR=0.97, 95% CI 0.89 to 1.05]). Compared with NSAIDs, tramadol with or without acetaminophen was less likely to achieve a 30% or more reduction in pain (RR=0.82, 95% CI 0.76 to 0.90), and was more likely to result in WDAEs (RR=2.86, 95% CI 2.23 to 3.66), total withdrawals (RR=1.68, 95% CI 1.47 to 1.93), and total AEs (RR=1.37, 95% CI 1.28 to 1.47). Evidence was insufficient for meta-analysis of fatal SAEs, drug dependence or addiction, quality of life, functional improvement, or use of rescue medications.

Conclusion Tramadol with or without acetaminophen did not differ significantly from other opioids, and was less effective and more poorly tolerated than NSAIDs. Short study duration, small sample size, extensive patient exclusion, and inconsistency in outcome reporting limit the scientific validity of conclusions.

Family physicians from Canada have indicated that pain management is challenging due to competing messages regarding undertreatment and overtreatment and a lack of education or expert guidance.1

Tramadol (with or without acetaminophen) is an opioid analgesic licensed for treating moderate to severe pain. In 2007, following the cyclooxygenase-2 inhibitor scandals and increased awareness of nonsteroidal anti-inflammatory drug (NSAID) organotoxicity, articles and guidelines positioned tramadol as a safer alternative to NSAIDs and other opioid analgesics.2 For example, in accordance with the World Health Organization (WHO) pain ladder, 2011 Canadian pain guidelines stated tramadol was effective for chronic pain and encouraged its use as preferable to more potent opioids because of lower rates of overdose, misuse, and addiction.3,4

Although initially marketed and popularized as a non-opioid analgesic, tramadol results in a similar amount of opioid agonism as codeine, with the WHO Expert Committee on Drug Dependence concluding it has a risk of addiction similar to opioids like morphine.5 Consequently, tramadol predominates the opioid crisis in Africa and the Middle East.6,7

In the early 2000s, the product monograph for tramadol was updated to include a serious warning for potential addiction, abuse, misuse, overdose, and death.8 A 2021 population-based cohort study determined that, compared with codeine, new prescriptions for tramadol were associated with a 2.3-fold increase in all-cause mortality.9 In 2022, Health Canada added tramadol to the existing list of opioids in schedule I of the Controlled Drugs and Substances Act and to the Narcotic Control Regulations.10

From 2007 to 2017, total opioid prescriptions declined across Canada, but prescriptions for tramadol were steady or increasing.11 The most recent data available show a 4% increase in tramadol prescriptions filled in Canada from 2015 to 2019.12 Given both its popularity as an analgesic and growing concerns regarding safety, we sought evidence comparing tramadol with opioids, NSAIDs, and acetaminophen.

METHODS

Data sources

This systematic review was conducted according to the Cochrane Handbook for Systematic Reviews of Interventions (Appendix 1, available from CFPlus*).13 We applied the Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol for quality and publication standards.

The electronic databases searched included the entire Ovid MEDLINE database, the Ovid MEDLINE Epub Ahead of Print database, Embase, and Evidence-Based Medicine Reviews (Cochrane Central Register of Controlled Trials) from 1946 to August 19, 2022. Detailed search strategies are provided in Appendix 2.* Additional manual searches to ensure completeness yielded 3 published Cochrane systematic reviews14-16 and 1 Canadian Agency for Drugs and Technologies in Health common drug review report from 2007 (personal communication with Dr Ken Bassett, Co-managing Director of the Therapeutics Initiative, March 11, 2020).

Eligibility criteria

Included studies met the following criteria: a population of adults with acute or chronic pain; an intervention of oral tramadol with or without acetaminophen (any dose or formulation); a comparator of oral or transdermal opioids with or without acetaminophen, oral NSAIDs, or acetaminophen (Appendix 1*); 1 or more outcomes of total adverse events (AEs), fatal serious AEs (SAEs), nonfatal SAEs, patient withdrawals from the study due to AEs (WDAEs), total withdrawals, drug dependence or withdrawal symptoms or measure of addiction, quality of life, functional improvement, clinically meaningful efficacy (proportion of patients with ≥30% or ≥50% pain reduction from baseline), and rescue medication use; and a double-blind randomized controlled trial (RCT) study design.

Study selection

Titles and abstracts of records identified through database searches were screened by 3 reviewers (J.A.O. and G.C., with contributions from Jano Klimas). Potentially relevant abstracts proceeded to full-text review and were each screened by 2 reviewers (J.A.O., G.C.). Any discrepancies in inclusion or exclusion reasons were resolved through discussion and consensus.

Data extraction

Two authors (J.A.O., G.C.) extracted data independently. All relevant data were extracted using Covidence software (https://www.covidence.org) and exported to Review Manager 5.4 for analysis.

Risk of bias assessment

Risk of bias of included studies was assessed by 2 reviewers (J.A.O., G.C.) independently and in duplicate using the Cochrane risk-of-bias tool for randomized trials 1.0.

Data synthesis and analysis

Outcomes with studies using the same definitions and units of measurement were pooled for meta-analysis using Review Manager 5.4. Differences between interventions were reported using summary risk ratios (RRs) with 95% confidence intervals (CIs), with statistically significant differences designated by P<.05, and heterogeneity between studies measured by I2. The Mantel-Haenszel method and a fixed-effects model were used to combine dichotomous outcomes data. When study data could not be pooled (eg, heterogeneity between studies in outcome definitions, measurement, or reporting), claims were narratively summarized. No sensitivity or subgroup analyses were undertaken.

RESULTS

Searches of electronic databases yielded 3184 records published from 1946 to August 19, 2022. Following removal of duplicates, the titles and abstracts of 3182 records were screened. The full texts of 119 records were assessed for eligibility. Overall, 36 texts (37 studies)17-52 met inclusion criteria (Figure 1).

Figure 1.
Figure 1.

PRISMA flow diagram

Study characteristics

Twenty-one studies involving 3205 participants compared tramadol with or without acetaminophen to opioids21-23,27-29,31,33-36,42-44,46-52; 15 studies (n=3931) compared it to NSAIDs17-19,24-26,30,32,37-41,45; and 1 study (n=20) compared tramadol to acetaminophen.20 Thirteen studies using an opioid comparator,21,23,27-29,31,34,46-48,50-52 and 8 using NSAIDs17,18,25,26,30,32,41,45 assessed acute pain; most studied immediate postprocedure pain (eg, dental extractions, acute trauma, and gynecologic procedures) but 1 continued to 2 weeks after rotator cuff repair.18 Eight opioid studies,22,33,35,36,42-44,49 1 acetaminophen study,20 and 7 NSAID studies19,24,37-40 assessed chronic pain, which was usually musculoskeletal, oncologic, or unspecified in nature. Trial durations ranged from 1 hour to 12 weeks. For a summary of pain types, contexts of use, and study durations, see Appendix 3*; study characteristics are listed in Appendix 4.*

Risk of bias

Figure 2 shows the consensus ratings for each of 8 risk of bias domains in all 36 included papers.17-52 All studies had low or unclear risk of bias for random sequence generation, allocation concealment, and blinding of outcome assessment. All but 1 study45 had unclear or low risk of bias from blinding of participants and personnel. Most studies had uncertain or high risk of bias due to incomplete and selective reporting of outcomes, incomplete outcome data, funding sources, and other biases. More detail can be found in Appendix 5.*

Figure 2.
Figure 2.

Risk of bias: Green represents low risk, yellow unclear risk, and red high risk of bias.

Outcome summaries and results of meta-analysis

The study outcomes of interest are described below and presented in detail in Appendix 6.* Tables 1 and 2 summarize measures that were meta-analyzed; corresponding forest plots are in Appendix 7.* Most studies did not report on efficacy outcomes of interest to this systematic review or prespecify thresholds for clinical relevance; however, many reported on changes in pain intensity, and a narrative summary of those claims is available from Appendix 8.*

View this table:
Table 1.

Tramadol compared with NSAIDs: Outcome results of meta-analyses.

View this table:
Table 2.

Tramadol compared with opioids: Outcome results of meta-analyses.

Outcomes versus acetaminophen. A single study20 compared tramadol with acetaminophen, but the study was too small (10 patients in each arm) to generate reliable conclusions.

Outcomes versus NSAIDs. Four NSAID comparator studies reported on mortality, and none reported any deaths.24,25,37 The pooled nonfatal SAEs did not differ between tramadol with or without acetaminophen and NSAIDs (9 studies, RR=1.24, 95% CI 0.38 to 4.06). There were more WDAEs among patients taking tramadol with or without acetaminophen than among patients taking NSAIDs (12 studies, RR=2.86, 95% CI 2.23 to 3.66), total patient withdrawals (13 studies, RR=1.68, 95% CI 1.47 to 1.93), and AEs (14 studies, RR=1.37, 95% CI 1.28 to 1.47). No NSAID studies reported on 50% or more pain reduction. Both studies from O’Donnell et al37 reported the proportion of patients with 30% or more pain reduction from baseline; fewer patients in the tramadol group compared with those taking celecoxib experienced that improvement (2 studies, RR=0.82, 95% CI 0.76 to 0.90).

Measures of drug dependence or addiction were assessed in 2 studies comparing tramadol and NSAIDs: Beaulieu et al19 found no significant difference in drug-liking index scores. DeLemos et al24 employed both an addiction scale and a physical dependence scale but only reported comparisons with placebo, not with NSAIDs. Quality of life and functional outcomes could not be meta-analyzed due to inconsistency of measurement and absence of standard, validated scales, and most studies reported no significant difference or made no claims regarding these metrics. Peters et al41 reported a significant difference favouring naproxen according to patient ratings of ability to proceed with normal activities. Rescue medication use was not meta-analyzed due to significant heterogeneity in definitions and reporting. In many studies, patients using rescue medications were withdrawn. Of the NSAID comparator studies reporting on rescue medication use, 5 studies17,19,25,32,45 found no difference and 1 made no claim.41

Outcomes versus opioids. There were no deaths in the 3 opioid studies reporting mortality.27,28,33 The pooled nonfatal SAEs did not differ between tramadol with or without acetaminophen and opioids (10 studies, RR=1.35, 95% CI 0.43 to 4.20). There were similar rates of total study withdrawals between tramadol with or without acetaminophen and opioid groups (17 studies, RR=0.93, 95% CI 0.78 to 1.11), WDAEs (16 studies, RR=0.99, 95% CI 0.80 to 1.22), and AEs (12 studies, RR=0.97, 95% CI 0.89 to 1.05).

Physical dependence or withdrawal symptoms were reported using various nonvalidated scales and could not be pooled for analysis. Two studies reported no difference: Leng et al33 found equivalent subjective opioid withdrawal symptoms 1 week after tramadol or transdermal buprenorphine was started for musculoskeletal pain. Mullican et al36 reported no signs of abuse or dependence on tramadol with acetaminophen or codeine with acetaminophen in patients with chronic lower back pain, but this outcome was not predefined, and it is not clear how it was measured. Most studies excluded patients with a history of substance use disorder.

Quality-of-life metrics were reported inconsistently and function was not assessed with any validated scale. Studies that reported some measure of quality of life reported no difference23,33 or mixed results.50 One study found tramadol resulted in a lower median stiffness duration but no change in stiffness score when compared with pentazocine in osteoarthritis.22 Two found no significant difference between study groups in mobility or activity impairment.23,28

Hewitt et al is the only opioid study to report the proportions of patients with 50% or more and 30% or more pain reductions and found no statistically significant differences between tramadol and hydrocodone.28

Rescue medication use was variably defined and reported and not able to be meta-analyzed. Of the 17 opioid comparator studies reporting rescue medication use, 8 claimed no difference,22,27,29,33,34,36,49,51 and 6 made no claim or did not permit rescue medication use.28,31,42,46,48,50 Zavareh et al52 found patients taking 50 mg of tramadol required less morphine as rescue medication in the 24 hours after cholecystectomy than did those in the combination 325 mg of acetaminophen and 10 mg of codeine group, but this tramadol dose is far higher in oral morphine equivalents than the codeine dose is.53 Two studies favoured the opioid comparator: Stubhaug et al47 stated that rescue medicine was needed less often in the acetaminophen-codeine group compared with 2 different tramadol dose groups after total hip replacement; Bindal et al21 found that for bladder discomfort, 1 patient in the tapentadol premedication group and 14 in the tramadol group required rescue medication.

DISCUSSION

Comparative data on analgesics facilitates informed discussions with patients about anticipated efficacy and harm. This review includes comparative studies from a range of settings, incorporating patients with both acute and chronic pain, and found no significant differences between tramadol with or without acetaminophen and opioid comparators for any safety or efficacy outcomes. When compared with NSAIDs, tramadol with or without acetaminophen was less effective at pain reduction of 30% or more and resulted in significantly higher WDAEs, total withdrawals, and total AEs.

Our systematic review differs slightly from existing Cochrane systematic reviews. Toupin April et al14 looked at osteoarthritis pain and separated tramadol from tramadol with acetaminophen, permitted open-label RCTs, and included both placebo and active comparators. They reported similar findings to our study, but unlike our study that found no difference, they did find low-quality evidence that tramadol alone had a greater risk of WDAEs compared with opioids.14 Duehmke et al found no clear therapeutic benefit of tramadol compared with active or placebo comparators for neuropathic pain.54 In the Wiffen et al study,55 very low-quality evidence suggested tramadol may offer some advantage compared with placebo, but it is not as effective as morphine for cancer-related pain.

We sought data on clinically meaningful effectiveness (a reduction in pain of ≥30% or ≥50%) in accordance with the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials consensus.56 Most trials did not report on these outcomes, which greatly limited meaningful efficacy comparisons. Confidence in study findings was limited by small sample sizes, noncomparable doses, imbalanced patient selection, and funding by manufacturers. In addition, dropout rates were high and just 15 studies did intention-to-treat analysis18,19,24,27,28,33,35-38,42,46-48; of those that did, 6 did not analyze all participants,19, 28,35,42,46,47 and 6 imputed missing data,24,27,33,36,42,48 increasing reporting biases, usually favouring tramadol.

Short durations and strict exclusion criteria limit generalizability. This is particularly concerning for real-world decision making, as opioid analgesics are often used for patients with chronic pain or with a history of substance use disorders. In addition, short studies may miss serious or uncommon adverse events and symptoms of dependence or addiction, as these tend to develop over months or years. A review focusing on tramadol for chronic pain is planned by Danish investigators, and their results may reinforce or refute our conclusions and decision to combine acute and chronic indications.57

Recent retrospective observational studies reveal a higher likelihood of prolonged opioid use in patients receiving a prescription of tramadol compared with those receiving other short-acting opioids.58,59 Given the persistent and overwhelming opioid crisis in Canada, the association is compelling enough to prompt concern about the addiction potential from tramadol exposure.

Conclusion

Compared to patients taking NSAIDs, patients taking tramadol with or without acetaminophen are less likely to achieve a 30% or more pain reduction from baseline and more likely to experience WDAEs, total withdrawals, and total AEs. Compared with opioids, tramadol with or without acetaminophen result in similar efficacy and harm. The use of tramadol should be considered carefully and monitored in the same ways as other opioid analgesics.

Acknowledgment

We thank Douglas Salzwedel for performing a full electronic database search for all relevant studies, Stephen Paul Adams for retrieving the records used in full-text assessment, and Jano Klimas for contributing initially to the title and abstract screenings. We also thank all members of the Therapeutics Initiative at the University of British Columbia for their knowledge and guidance in this review.

Footnotes

  • ↵* Appendices 1 to 8 are available from https://www.cfp.ca. Go to the full text of the article online and click on the CFPlus tab.

  • Contributors

    All authors formulated the research question and selected outcomes of interest. Drs Gloria Chu and Jessica A. Otte completed the title and abstract screenings, the full-text reviews, the risk of bias assessments, and data extractions (with consensus generation). Dr Chu did statistical analysis and generated the foundation and tables for the manuscript. Dr Otte wrote and revised the text for publication. Dr Benji Heran provided process guidance throughout. Drs Heran and Ken Bassett reviewed and edited the manuscript.

  • Competing interests

    All authors are salaried members of the Therapeutics Initiative at the University of British Columbia in Vancouver.

  • This article has been peer reviewed.

  • Cet article a fait l’objet d’une révision par des pairs

References

  1. 1.↵
    1. Goodwin J,
    2. Kirkland S
    . Barriers and facilitators encountered by family physicians prescribing opioids for chronic non-cancer pain: a qualitative study. Health Promot Chronic Dis Prev Can. 2021 Jun;41(6):182-9. doi: 10.24095/hpcdp.41.6.03.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Schug SA
    . The role of tramadol in current treatment strategies for musculoskeletal pain. Ther Clin Risk Manag. 2007 Oct;3(5):717-23.
    OpenUrlPubMed
  3. 3.↵
    1. Anekar AA,
    2. Hendrix JM,
    3. Cascella M
    . WHO Analgesic Ladder. [Updated 2023 Apr 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan [cited 2025 Jul 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554435.
  4. 4.↵
    1. Kahan M,
    2. Mailis-Gagnon A,
    3. Wilson L,
    4. Srivastava A, et al
    . Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 1: general population. Can Fam Physician. 2011 Nov;57(11):1257-66, e407-18.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Expert Committee on Drug Dependence
    . Critical Review Report: Tramadol [Internet]. World Health Organization; 2018 Nov [cited 2025 Jul 8]. Available from: https://ecddrepository.org/sites/default/files/2023-04/tramadol.pdf.
  6. 6.↵
    1. Salm-Reifferscheidt L.
    Tramadol: Africa’s opioid crisis. Lancet. 2018 May 19;391(10134):1982-3. doi: 10.1016/S0140-6736(18)31073-0. Epub 2018 May 17.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Schmall E,
    2. Galofaro C
    . How tramadol, touted as safer opioid, became 3rd world peril. Associated Press [Internet]. 2019 Dec 13 [cited 2025 Jul 8]. Available from: https://apnews.com/article/united-nations-india-ap-top-news-opioids-health-56b0e448d317684a2344b5efcd9cca37.
  8. 8.↵
    1. AA Pharma Inc.
    Product monograph including patient medication information: Tramadol: Tramadol hydrochloride tablets USP, 50mg, Opioid Analgesic [Internet]. AA Pharma Inc; 2018 Jun 7. Available from: https://pdf.hres.ca/dpd_pm/00045851.PDF.
  9. 9.↵
    1. Xie J,
    2. Strauss VY,
    3. Martinez-Laguna D,
    4. Carbonell-Abella C, et al
    . Association of Tramadol vs Codeine Prescription Dispensation With Mortality and Other Adverse Clinical Outcomes. JAMA. 2021 Oct 19;326(15):1504-15. doi: 10.1001/jama.2021.15255.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Canada Gazette
    . Order Amending Schedule I to the Controlled Drugs and Substances Act (Tramadol): SOR/2021-44 [Internet]. Government of Canada; 2021 Mar 18 [cited 2025 Jul 8]. Available from: https://canadagazette.gc.ca/rp-pr/p2/2021/2021-03-31/html/sor-dors44-eng.html.
  11. 11.↵
    1. Fischer B,
    2. Kurdyak P,
    3. Jones W
    . Tramadol dispensing patterns and trends in Canada, 2007-2016. Pharmacoepidemiol Drug Saf. 2019 Mar;28(3):396-400. doi: 10.1002/pds.4679. Epub 2018 Dec 12.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Health Canada
    . Summary Safety Review—Tramadol-containing products—Assessing the Potential Risk of Hallucinations [Internet]. Government of Canada; 2020 Dec 29 [cited 2025 Jul 8]. Available from: https://dhpp.hpfb-dgpsa.ca/review-documents/resource/SSR00253.
  13. 13.↵
    1. Higgins JPT,
    2. Thomas J,
    3. Chandler J,
    4. Cumpston M, et al
    . Cochrane handbook for systematic reviews of interventions version 6.2. Cochrane; 2021 Feb [cited 2025 Jul 8]. Available from: https://www.cochrane.org/authors/handbooks-and-manuals/handbook.
  14. 14.↵
    1. Toupin April K,
    2. Bisaillon J,
    3. Welch V,
    4. Maxwell LJ, et al
    . Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2019 May 27;5(5):CD005522. doi: 10.1002/14651858.CD005522.pub3.
    OpenUrlCrossRefPubMed
  15. 15.
    1. Duehmke RM,
    2. Derry S,
    3. Wiffen PJ,
    4. Bell RF, et al
    . Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jun 15;6(6):CD003726. doi: 10.1002/14651858.CD003726.pub4.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Wiffen PJ,
    2. Derry S,
    3. Moore RA
    . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017 May 16;5(5):CD012508. doi: 10.1002/14651858.CD012508.pub2.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Oh JH,
    2. Seo HJ,
    3. Lee YH,
    4. Choi HY, et al
    . Do Selective COX-2 Inhibitors Affect Pain Control and Healing After Arthroscopic Rotator Cuff Repair? A Preliminary Study. Am J Sports Med. 2018 Mar;46(3):679-86. doi: 10.1177/0363546517744219. Epub 2017 Dec 18.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Akinbade AO,
    2. Ndukwe KC,
    3. Owotade FJ
    . Comparative Analgesic Effects of Ibuprofen, Celecoxib and Tramadol after third Molar Surgery: A Randomized Double Blind Controlled Trial. J Contemp Dent Pract. 2018 Nov 1;19(11):1334-40.
    OpenUrlPubMed
  19. 19.↵
    1. Beaulieu AD,
    2. Peloso PM,
    3. Haraoui B,
    4. Bensen W, et al
    . Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: a randomized controlled trial. Pain Res Manag. 2008 Mar-Apr;13(2):103-10. doi: 10.1155/2008/903784.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Bianchi M,
    2. Broggini M,
    3. Balzarini P,
    4. Baratelli E, et al
    . Effects of tramadol on synovial fluid concentrations of substance P and interleukin-6 in patients with knee osteoarthritis: comparison with paracetamol. Int Immunopharmacol. 2003 Dec;3(13-14):1901-8. doi: 10.1016/j.intimp.2003.08.011.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Bindal K,
    2. Kumar N,
    3. Oberoi D,
    4. Biswas M
    . Comparison between pre-emptive oral tramadol and tapentadol for attenuation of catheter-related bladder discomfort and surgical stress response in patients undergoing transurethral resection of prostate: A prospective, randomised, double-blind trial. Indian J Anaesth. 2021;65(Suppl 4):S156-62.
    OpenUrlPubMed
  22. 22.↵
    1. Bird HA,
    2. Hill J,
    3. Stratford ME,
    4. Fenn GC, et al
    . A double-blind cross-over study comparing the analgesic efficacy of tramadol with pentazocine in patients with osteoarthritis. J Drug Dev Clin Pract. 1995;7(3):181-8.
    OpenUrl
  23. 23.↵
    1. Crighton IM,
    2. Hobbs GJ,
    3. Wrench IJ
    . Analgesia after day case laparoscopic sterilisation. A comparison of tramadol with paracetamol/dextropropoxyphene and paracetamol/codeine combinations. Anaesthesia. 1997 Jul;52(7):649-52. doi: 10.1111/j.1365-2044.1997.142-az0146.x.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. DeLemos BP,
    2. Xiang J,
    3. Benson C,
    4. Gana TJ, et al
    . Tramadol hydrochloride extended-release once-daily in the treatment of osteoarthritis of the knee and/or hip: a double-blind, randomized, dose-ranging trial. Am J Ther. 2011 May;18(3):216-26. doi: 10.1097/MJT.0b013e3181cec307.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Desjardins P,
    2. Alvarado F,
    3. Gil M,
    4. González M, et al
    . Efficacy and Safety of Two Fixed-Dose Combinations of Tramadol Hydrochloride and Diclofenac Sodium in Postoperative Dental Pain. Pain Med. 2020 Oct 1;21(10):2447-57. doi: 10.1093/pm/pnaa124.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Doroschak AM,
    2. Bowles WR,
    3. Hargreaves KM
    . Evaluation of the combination of flurbiprofen and tramadol for management of endodontic pain. J Endod. 1999 Oct;25(10):660-3. doi: 10.1016/S0099-2399(99)80350-1.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Fricke JR Jr,
    2. Karim R,
    3. Jordan D,
    4. Rosenthal N.
    A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery. Clin Ther. 2002 Jun;24(6):953-68. doi: 10.1016/s0149-2918(02)80010-8.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Hewitt DJ,
    2. Todd KH,
    3. Xiang J,
    4. Jordan DM, et al
    . Tramadol/acetaminophen or hydrocodone/acetaminophen for the treatment of ankle sprain: a randomized, placebo-controlled trial. Ann Emerg Med. 2007 Apr;49(4):468-80, 480.e1-2. doi: 10.1016/j.annemergmed.2006.08.030. Epub 2006 Nov 20.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Kampe S,
    2. Wolter K,
    3. Warm M,
    4. Dagtekin O, et al
    . Clinical equivalence of controlled-release oxycodone 20 mg and controlled-release tramadol 200 mg after surgery for breast cancer. Pharmacology. 2009;84(5):276-81. doi: 10.1159/000242998. Epub 2009 Oct 1.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Karabayirli S,
    2. Ayrim AA,
    3. Muslu B
    . Comparison of the analgesic effects of oral tramadol and naproxen sodium on pain relief during IUD insertion. J Minim Invasive Gynecol. 2012 Sep-Oct;19(5):581-4. doi: 10.1016/j.jmig.2012.04.004. Epub 2012 Jul 4.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Kupers R,
    2. Callebaut V,
    3. Debois V,
    4. Camu F, et al
    . Efficacy and safety of oral tramadol and pentazocine for postoperative pain following prolapsed intervertebral disc repair. Acta Anaesthesiol Belg. 1995;46(1):31-7.
    OpenUrlPubMed
  32. 32.↵
    1. Latif D,
    2. Darweesh FF,
    3. Osman OM,
    4. Abdelhakim AM, et al
    . Oral tramadol versus oral celecoxib for analgesia after mediolateral episiotomy repair in obese primigravidae: a randomized controlled trial. Int Urogynecol J. 2021 Sep;32(9):2465-72. doi: 10.1007/s00192-020-04411-4. Epub 2020 Jul 20.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Leng X,
    2. Li Z,
    3. Lv H,
    4. Zheng Y, et al
    . Effectiveness and Safety of Transdermal Buprenorphine Versus Sustained-release Tramadol in Patients With Moderate to Severe Musculoskeletal Pain: An 8-Week, Randomized, Double-Blind, Double-Dummy, Multicenter, Active-controlled, Noninferiority Study. Clin J Pain. 2015 Jul;31(7):612-20. doi: 10.1097/AJP.0000000000000144.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Mitra S,
    2. Ahuja V,
    3. Kaushik R
    . Comparative study of analgesic efficacy and tolerability of oral tapentadol-paracetamol combination vs. Oral tramadol-paracetamol combination for postoperative pain relief in patients undergoing hernia surgery. Acta Anaesthesiologica Belgica. 2017;68(4):199-204.
    OpenUrl
  35. 35.↵
    1. Müller FO,
    2. Odendaal CL,
    3. Müller FR,
    4. Raubenheimer J, et al
    . Comparison of the efficacy and tolerability of a paracetamol/codeine fixed-dose combination with tramadol in patients with refractory chronic back pain. Arzneimittelforschung. 1998 Jun;48(6):675-9.
    OpenUrlPubMed
  36. 36.↵
    1. Mullican WS,
    2. Lacy JR; TRAMAP-ANAG-006 Study Group
    . Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther. 2001 Sep;23(9):1429-45. doi: 10.1016/s0149-2918(01)80118-1.
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. O’Donnell JB,
    2. Ekman EF,
    3. Spalding WM,
    4. Bhadra P, et al
    . The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009 Nov-Dec;37(6):1789-802. doi: 10.1177/147323000903700615.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Ouncharoen T
    . Tramadol versus naproxen for pain relief in knee osteoarthritis: a pragmatic randomized controlled trial. Clin Academia. 2018;42(2):53-64. Available from: https://he02.tci-thaijo.org/index.php/theclinicalacademia/article/view/173066.
    OpenUrl
  39. 39.
    1. Pavelka K,
    2. Pelisková Z,
    3. Stehlíková H,
    4. Ratcliffe S, et al
    . Intraindividual differences in pain relief and functional improvement in osteoarthritis with diclofenac or tramadol. Clin Drug Investig. 1998;16(6):421-9. doi: 10.2165/00044011-199816060-00002.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Peeva E,
    2. Beals CR,
    3. Bolognese JA,
    4. Kivitz AJ, et al
    . A walking model to assess the onset of analgesia in osteoarthritis knee pain. Osteoarthritis Cartilage. 2010 May;18(5):646-53. doi: 10.1016/j.joca.2009.12.008. Epub 2010 Feb 6.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Peters AA,
    2. Witte EH,
    3. Damen AC,
    4. Holm JP, et al
    . Pain relief during and following outpatient curettage and hysterosalpingography: a double blind study to compare the efficacy and safety of tramadol versus naproxen. Cobra Research Group. Eur J Obstet Gynecol Reprod Biol. 1996 May;66(1):51-6. doi: 10.1016/0301-2115(96)02381-0.
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Rauck RL,
    2. Ruoff GE,
    3. McMillen JI
    . Comparison of tramadol and acetaminophen with codeine for long-term pain management in elderly patients. Curr Ther Res Clin Exp. 1994;55(12):1417-31.
    OpenUrl
  43. 43.
    1. Rico MA,
    2. Cura MA,
    3. Harbst H,
    4. Palominos A, et al
    . Assessment of tramadol as an alternative opioid instead of codiene at the second step of the WHO analgesic scale. Rev Soc Esp Dolor. 2000;7(6):345-53. Spanish.
    OpenUrl
  44. 44.↵
    1. Rodriguez RF,
    2. Bravo LE,
    3. Castro F,
    4. Montoya O, et al
    . Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med. 2007 Feb;10(1):56-60. doi: 10.1089/jpm.2006.0117.
    OpenUrlCrossRefPubMed
  45. 45.↵
    1. Romero I,
    2. Turok D,
    3. Gilliam M
    . A randomized trial of tramadol versus ibuprofen as an adjunct to pain control during vacuum aspiration abortion. Contraception. 2008 Jan;77(1):56-9. doi: 10.1016/j.contraception.2007.09.008. Epub 2007 Nov 26.
    OpenUrlCrossRefPubMed
  46. 46.↵
    1. Smith AB,
    2. Ravikumar TS,
    3. Kamin M,
    4. Jordan D, et al
    . Combination tramadol plus acetaminophen for postsurgical pain. Am J Surg. 2004 Apr;187(4):521-7. doi: 10.1016/j.amjsurg.2003.12.038.
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Stubhaug A,
    2. Grimstad J,
    3. Breivik H
    . Lack of analgesic effect of 50 and 100 mg oral tramadol after orthopaedic surgery: a randomized, double-blind, placebo and standard active drug comparison. Pain. 1995 Jul;62(1):111-8. doi: 10.1016/0304-3959(95)00056-X.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Turturro MA,
    2. Paris PM,
    3. Larkin GL
    . Tramadol versus hydrocodone-acetaminophen in acute musculoskeletal pain: a randomized, double-blind clinical trial. Ann Emerg Med. 1998 Aug;32(2):139-43. doi: 10.1016/s0196-0644(98)70127-1.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Wilder-Smith CH,
    2. Schimke J,
    3. Osterwalder B,
    4. Senn HJ.
    Oral tramadol, a mu-opioid agonist and monoamine reuptake-blocker, and morphine for strong cancer-related pain. Ann Oncol. 1994 Feb;5(2):141-6. doi: 10.1093/oxfordjournals.annonc.a058765.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Wilder-Smith CH,
    2. Hill L,
    3. Osler W,
    4. O’Keefe S.
    Effect of tramadol and morphine on pain and gastrointestinal motor function in patients with chronic pancreatitis. Dig Dis Sci. 1999 Jun;44(6):1107-16. doi: 10.1023/a:1026607703352.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Wirz S,
    2. Wartenberg HC,
    3. Wittmann M,
    4. Nadstawek J
    . Post-operative pain therapy with controlled release oxycodone or controlled release tramadol following orthopedic surgery: A prospective, randomized, double-blind investigation. Pain Clinic. 2005;17(4):367-76.
    OpenUrl
  52. 52.↵
    1. Zavareh SM,
    2. Kashefi P,
    3. Saghaei M,
    4. Emami H
    . Pre emptive analgesia for reducing pain after cholecystectomy: Oral tramadol vs. acetaminophen codeine. Adv Biomed Res. 2013 Mar 6;2:12. doi: 10.4103/2277-9175.107964.
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. McPherson ML
    . Demystifying Opioid Conversion Calculations: A Guide for Effective Dosing. 2nd ed. Bethesda (MD): ASHP; 2018.
  54. 54.↵
    1. Duehmke RM,
    2. Derry S,
    3. Wiffen PJ,
    4. Bell RF, et al
    . Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev. 2017 Jun 15;6(6):CD003726. doi: 10.1002/14651858.CD003726.pub4.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Wiffen PJ,
    2. Derry S,
    3. Moore RA
    . Tramadol with or without paracetamol (acetaminophen) for cancer pain. Cochrane Database Syst Rev. 2017 May 16;5(5):CD012508. doi: 10.1002/14651858.CD012508.pub2.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Dworkin RH,
    2. Turk DC,
    3. Wyrwich KW,
    4. Beaton D, et al
    . Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008 Feb;9(2):105-21. doi: 10.1016/j.jpain.2007.09.005. Epub 2007 Dec 11.
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Barakji J,
    2. Korang SK,
    3. Feinberg JB,
    4. Maagaard M, et al
    . Tramadol for chronic pain in adults: protocol for a systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. Syst Rev. 2023 Aug 22;12(1):145. doi: 10.1186/s13643-023-02307-0.
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Thiels CA,
    2. Habermann EB,
    3. Hooten WM,
    4. Jeffery MM
    . Chronic use of tramadol after acute pain episode: cohort study. BMJ. 2019 May 14;365:l1849. doi: 10.1136/bmj.l1849.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Shah A,
    2. Hayes CJ,
    3. Martin BC
    . Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use—United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017 Mar 17;66(10):265-9. doi: 10.15585/mmwr.mm6610a1.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Respond to this article
Tramadol (with or without acetaminophen) efficacy and harm
Jessica A. Otte, Gloria Chu, Benji Heran, Ken Bassett
Canadian Family Physician Sep 2025, 71 (9) 574-581; DOI: 10.46747/cfp.7109574
Twitter logo Facebook logo Mendeley logo

Jump to section

Subjects